Circulating peroxisome proliferator-activated receptor γ is elevated in systemic sclerosis.

Area of Science:

• Rheumatology
• Immunology
• Metabolic research

Background:

• Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis and vascular damage.
• Peroxisome proliferator-activated receptor γ (PPAR-γ) has known anti-fibrotic and immunomodulatory properties.
• PPAR-γ may play a role in linking cell metabolism and fibrosis in SSc.

Purpose of the Study:

• To quantify serum PPAR-γ levels in SSc patients.
• To investigate the correlation between PPAR-γ levels and SSc clinical characteristics.
• To explore associations with SSc subtype, disease duration, and organ involvement.

Main Methods:

• Serum PPAR-γ levels were measured using ELISA in 22 SSc patients and matched healthy controls.
• Clinical data included SSc subtype, autoantibodies, interstitial lung disease, and modified Rodnan skin score (mRSS).
• Statistical analyses included t-tests, Mann-Whitney-U, and correlation analyses.

Main Results:

• PPAR-γ concentration was significantly higher in SSc patients compared to controls (p=0.007).
• Elevated PPAR-γ was most pronounced in diffuse SSc patients (p=0.004), correlating with higher mRSS.
• No significant association was found between PPAR-γ levels and hs-CRP, organ involvement, disease duration, or Raynaud's phenomenon.

Conclusions:

• Serum PPAR-γ is elevated in SSc patients, especially in the diffuse subtype with higher skin scores.
• The origin and precise biological significance of elevated circulating PPAR-γ in SSc require further investigation.
• PPAR-γ may represent a potential biomarker or therapeutic target in Systemic sclerosis.